Treatment Outcomes after Postoperative Radiotherapy in Triple-Negative Breast Cancer: Multi-Institutional Retrospective Study (KROG 17-05)

Author:

Kim Jin Hee1ORCID,Byun Sang Jun1ORCID,Kim Myeongsoo1ORCID,Shin Kyung Hwan2,Kim Dong Yun23,Lee Han Byoel4,Kim Tae Hyun5ORCID,Kim Yeon Joo6,Kim Yong Bae6,Chang Jee Suk6ORCID,Kim Kyubo78ORCID,Lee Sun Young9ORCID

Affiliation:

1. Department of Radiation Oncology, Dongsan Hospital, Keimyung University School of Medicine, 1035 Dalgubeol-daero Dalseo-gu, Daegu 42601, Republic of Korea

2. Department of Radiation Oncology, Seoul National University College of Medicine, Seoul 03080, Republic of Korea

3. Department of Radiation Oncology, Chung-Ang University Hospital, Seoul 06973, Republic of Korea

4. Department of Surgery, Seoul National University College of Medicine, Seoul 03080, Republic of Korea

5. Department of Radiation Oncology, Proton Therapy Center, National Cancer Center, Goyang 10408, Republic of Korea

6. Department of Radiation Oncology, Yonsei University College of Medicine, Seoul 03722, Republic of Korea

7. Department of Radiation Oncology, Ewha Womans University School of Medicine, Seoul 07804, Republic of Korea

8. Department of Radiation Oncology, Seoul National University Bundang Hospital, Seoul 03080, Republic of Korea

9. Department of Radiation Oncology, Chonbuk National University Hospital, Jeonju 54907, Republic of Korea

Abstract

Background: We designed a multi-institutional retrospective study to investigate the previously unreported failure pattern, survivals, and prognostic factors after postoperative radiotherapy (PORT) in triple negative breast cancer (TNBC) patients in South Korea. Materials and Methods: We retrospectively reviewed 699 patients with TNBC who underwent PORT at six institutions between 2008 and 2010. The median follow-up period was 94 months (range: 7–192 months). There were 216, 380, and 100 patients in stages I, II, and III, respectively. Results: After 94 months post-treatment, all patients with pathologic complete remission after neoadjuvant chemotherapy were alive without any failure. Distant metastasis was the main cause of failure. The 5-year overall survival rate was 91.4%, 5-year loco-regional relapse-free survival rate (LRRFS) was 92.3%, 5-year distant metastasis-free survival rate (DMFS) was 89.4%, and 5-year disease-free survival rate (DFS) was 85.2%. On multivariate (Cox) analysis, T and N stages were significant prognostic factors for survival, and lympho-vascular invasion (LVI) was a significant factor for LRRFS and DMFS. Ki-67 expression was significantly associated with LRRFS and DFS. Conclusion: We verified that T and N stages, LVI, and Ki-67 expression were significantly associated with survival outcomes after PORT in TNBC.

Publisher

MDPI AG

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3